home / stock / abus / abus short
Short Information | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,371,018 |
Total Actual Volume | 23,407,404 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 168,551 |
Average Short Percentage | 17.59% |
Is there a ABUS Short Squeeze or Breakout about to happen?
See the ABUS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-17-2024 | $3.8 | $3.78 | $3.8299 | $3.67 | 1,255,643 | 216,170 | 17.22% |
07-16-2024 | $3.79 | $3.88 | $3.89 | $3.73 | 1,405,430 | 236,133 | 16.8% |
07-15-2024 | $3.54 | $3.75 | $3.79 | $3.54 | 1,342,628 | 219,633 | 16.36% |
07-12-2024 | $3.55 | $3.59 | $3.65 | $3.51 | 849,268 | 173,512 | 20.43% |
07-11-2024 | $3.415 | $3.51 | $3.52 | $3.3993 | 1,246,153 | 147,449 | 11.83% |
07-10-2024 | $3.4 | $3.41 | $3.43 | $3.34 | 1,048,923 | 133,754 | 12.75% |
07-09-2024 | $3.24 | $3.4 | $3.41 | $3.24 | 1,013,124 | 230,366 | 22.74% |
07-08-2024 | $3.14 | $3.26 | $3.32 | $3.135 | 1,210,639 | 237,995 | 19.66% |
07-05-2024 | $3.15 | $3.12 | $3.15 | $3.05 | 663,041 | 256,707 | 38.72% |
07-03-2024 | $3.15 | $3.16 | $3.22 | $3.13 | 661,835 | 130,003 | 19.64% |
07-02-2024 | $3.12 | $3.13 | $3.14 | $3.09 | 856,611 | 135,273 | 15.79% |
07-01-2024 | $3.07 | $3.12 | $3.15 | $3.05 | 722,406 | 115,392 | 15.97% |
06-28-2024 | $3.12 | $3.09 | $3.2 | $2.99 | 4,407,796 | 138,316 | 3.14% |
06-27-2024 | $3.03 | $3.1 | $3.14 | $3.03 | 644,004 | 133,707 | 20.76% |
06-26-2024 | $3.02 | $3.01 | $3.03 | $2.945 | 645,297 | 166,203 | 25.76% |
06-25-2024 | $3.06 | $3.05 | $3.08 | $2.99 | 598,659 | 114,462 | 19.12% |
06-24-2024 | $3.09 | $3.07 | $3.115 | $3.03 | 734,374 | 69,882 | 9.52% |
06-21-2024 | $3 | $3.05 | $3.07 | $2.96 | 2,110,757 | 144,797 | 6.86% |
06-20-2024 | $3 | $2.95 | $3.01 | $2.915 | 1,289,773 | 219,851 | 17.05% |
06-18-2024 | $3.07 | $3.01 | $3.07 | $3.01 | 701,043 | 151,413 | 21.6% |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment ...